Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well everolimus works in treating patients with
previously treated unresectable or metastatic esophageal cancer or stomach cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Oncology Research International
Collaborators:
National Cancer Institute (NCI) University of California, Los Angeles